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Abstract: A selective and sensitive ultra performance liquid chromatography-tandem mass spectrometry method
was developed for the simultaneous determination of losartan (LOS), EXP-3174, which is an active metabolite LOS
carboxylic acid, and hydrochlorothiazide (HCTZ) in human plasma. Solid-phase extraction was carried out on Oasis
HLB cartridges with 100 µ L of plasma to give an extraction recovery in the range of 88.5%–102.5% for the three analytes.
Chromatography on a BEH C18 column aﬀorded baseline separation of all the analytes within 2.4 min using 1.0% formic
acid in water and acetonitrile (15:85, v/v) as the mobile phase. Quantitation was performed with multiple reaction
monitoring in the negative ionization mode. The response of the method was linear over a dynamic range of 0.5–500,
1.0–750, and 0.25–150 ng/mL for LOS, EXP-3174, and HCTZ, respectively. Extent of signal suppression/enhancement
was examined through postcolumn infusion. The eﬀect of matrix components was evaluated by postextraction spiking
and calculation of the slope of calibration lines. The method was successfully applied to a bioequivalence study of 50
mg losartan and 12.5 mg hydrochlorothiazide tablet formulation in 65 healthy human subjects. Reproducibility of the
method was shown by reanalysis of 213 incurred samples.
Key words: Losartan, EXP-3174, hydrochlorothiazide, solid phase extraction, UPLC-MS/MS, human plasma

1. Introduction
Losartan (LOS) is a nonpeptide, orally active, and selective angiotensin II Type 1 (AT 1 ) receptor antagonist drug used mainly to treat hypertension associated with heart failure or renal impairment. It diﬀers from
angiotensin-converting enzyme (ACE) inhibitors by producing direct antagonism II receptors. 1,2 LOS is well
absorbed following oral administration with an oral bioavailability of about 33% and reaches peak serum levels
in 1.0 h. It undergoes significant first-pass metabolism to produce an active 5-carboxylic acid metabolite, designated as EXP-3174, which is mediated by cytochrome P450 enzymes CYP3A4 and CYP2C9. This metabolite
is a long-acting (up to 24 h), noncompetitive antagonist at the AT 1 receptor and contributes to the pharmacological eﬀects of LOS. It is 10–40 times more potent in blocking AT 1 receptors than the parent drug. 3
Hydrochlorothiazide (HCTZ) is a popular diuretic of the thiazide class that reduces plasma volume by increasing the excretion of sodium, chloride, and water. The decrease in plasma volume results in counter-regulatory
stimulation of the rennin-angiotensin system and the sympathetic nervous system. 4 Thus, the complimentary
action of an angiotensin II receptor antagonist and a thiazide has led to their extensive use in the treatment of
∗ Correspondence:
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patients with overt heart failure. Clinical studies have demonstrated antihypertensive eﬃcacy and tolerability of
LOS-HCTZ combination therapy in patients with moderate-to-severe essential hypertension, which is otherwise
inadequately controlled by monodrug therapy. 5,6 Thus, with the advancement of medical science, there is an
immense role of combination therapy with multiple drugs or at least two drugs having diﬀerent modes of action
in the treatment of hypertension. 7
Several methods are reported for the quantitation of LOS, alone, 8−10 in the presence of its active
metabolite, EXP-3174, 11−18 with other angiotensin II receptor antagonists, 19,20 and also with other classes
of drugs in binary, 21,22 ternary 23,24 and quaternary 25 combinations in diﬀerent biological matrices. Similarly,
a number of bioanalytical methods are presented for the determination of HCTZ as a single analyte, 26−29 and
in the presence of diﬀerent antihypertensive drugs in binary 30−40 and ternary 41,42 combinations in various
biological fluids including human plasma, 26−33,36−42 human urine, 32,34 and rat plasma. 35
So far few methods are reported for the simultaneous analysis of LOS, EXP-3174, and HCTZ. 7,43−47
Amongst these methods some have reported determination of LOS and HCTZ, 43,44 while the rest deal with the
analysis of EXP-3174 along with LOS and HCTZ. 7,45−47 Kolocouri et al. 45 have reported a LC-MS/MS method
for the simultaneous determination of all three analytes in human plasma. However, the total analysis time was
substantially high, involving a lengthy sample preparation protocol through a fully automated 96-well-format–
based solid phase extraction. Moreover, the calibration range set for the analytes is narrow and the method
is not adequately sensitive for pharmacokinetic applications. Two other methods describe separate procedures
for sample preparation and chromatographic separation of LOS, EXP-3174, and HCTZ in human plasma. 46,47
Both these methods have low sensitivity and long analysis time (5–10 min). Goswami et al. 7 have presented a
promising LC-MS/MS method but the analytes (LOS and EXP-3174) were not chromatographically resolved,
three separate internal standards were used for each of the analyte, and a large plasma volume was employed
(500 µ L) for sample preparation.
So far there are no methods based on UPLC-MS/MS for the simultaneous determination of LOS, EXP3174, and HCTZ in human plasma. Thus, the objective of this work was to develop and fully validate a selective,
rapid, and adequately sensitive method for the simultaneous estimation of all three analytes. The method
presents an eﬃcient solid-phase extraction of the analytes with quantitative recovery. The total analysis time
(extraction and chromatography) was approximately 10 min. Additionally, the method presented has higher
sensitivity and employs a much lower plasma sample for processing compared to all other reported methods.
The method was successfully applied to a bioequivalence study of 50 mg losartan potassium and 12.5 mg
hydrochlorothiazide hydrochloride fixed dose tablet formulation in 65 healthy human subjects. Further, the
reproducibility of the method was suitably demonstrated by reanalysis of 213 incurred samples.

2. Results and discussion
2.1. Method development
Selective determination of LOS, EXP-3174, and HCTZ in human plasma is diﬃcult due to their diﬀerent
physicochemical properties. All three analytes are weak acids with pKa of 5.6 and 5.4 for LOS and EXP-3174,
respectively, corresponding to the acidic nitrogen protons in the tetrazole ring, and another pKa of 4.2 for
EXP-3174 due to the carboxy group. 11 Similarly, HCTZ has pKa values of 7.9 and 9.2 due to the secondary
amine and sulfonamide group, respectively. 43 Due to the significant diﬀerence in pKa values it was imperative
to set optimum conditions for plasma extraction, chromatography, and mass detection for their simultaneous
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determination. Mass spectrometric detection was preferred compared to UV, 8,9,11,21,25,26,31,36 diode array, 34,35
or fluorescence detection, 15,22,23 to attain the desired sensitivity and selectivity of the method. For quantitation,
earlier reports have used negative polarity for LOS, EXP-3174, and HCTZ 7,44,45 to achieve adequate response for
their simultaneous analysis. Moreover, negative ionization mode is selective and highly sensitive for compounds
with high electron aﬃnity. Thus, negative ionization mode was selected to fragment the analytes and to obtain
intense and consistent product ions. The deprotonated precursor ions [M – H] − at m/z 421.2, 435.2, and 295.9
were observed in Q1 MS for LOS, EXP-3174, and HCTZ, respectively. Characteristic product ions found in Q3

Figure 1. Product ion mass spectra of (a) losartan (m/z 421.2 → 127.0, scan range 50–450 amu), (b) EXP-3174 (m/z
435.2 → 157.0, scan range 50–450 amu) and (c) hydrochlorothiazide (m/z 295.9 → 268.9, scan range 20–340 amu) in
negative ionization mode.
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Figure 2.

Product ion mass spectra of (a) candesartan (m/z 439.1 → 309.9, scan range 50–450 amu) and (b)

hydroflumethiazide (m/z 329.9 → 239.0, scan range 20–340 amu) in negative ionization mode.

MS were at m/z 335.0, 227.0, 157.0, and 127.0 for LOS; m/z 390.8, 355.2, 255.0, and 157.0 for EXP-3174; and
m/z 268.9, 204.6, 126.0, and 78.0 for HCTZ, respectively. However, the most stable and consistent fragment
ions selected were m/z 127.0 and 157.0 for LOS and EXP-3174, respectively, having the imidazole ring (Figures
1a and 1b). For HCTZ, the major product ion was found at m/z 268.9 due to elimination of neutral species
(HCN) from the precursor ion (Figure 1c). For the internal standard candesartan (CAN), the fragment at m/z
309.9 possessing the tetrazole ring (Figure 2a) and at m/z 239.0 (due to breaking up of benzthiazide ring) for
hydroflumethiazide (HFMZ) (Figure 2b) were selected as the most abundant ions.
The chromatographic elution of the analytes on a Waters Acquity UPLC BEH C18 (50 × 2.1 mm, 1.7
µ m) column was initiated as a rapid, sensitive, and rugged analytical method covering the dynamic linear range.
The selection of mobile phase was crucial for synchronized determination of all the drugs having diﬀerent pKa
values. Thus, the pH of the mobile phase, buﬀer concentration, and choice and proportion of diluents were very
important for chromatographic resolution with adequate response to achieve the desired sensitivity. Initially,
acetonitrile/methanol with 10 mM ammonium acetate buﬀer (pH 6.5) gave higher response for LOS, EXP3174, and CAN; however, the response for HCTZ and HFMZ was not reproducible. The signal was severely
compromised at lower limit of quantitation (LLOQ) levels even after altering the concentration of buﬀer from
10 mM to 1.0 mM. Further, the chromatography was better with a higher response using an acetonitrile-buﬀer
as compared to a methanol-buﬀer combination. Moreover, lowering the acetonitrile content in the mobile phase
resulted in an increase in the retention of LOS and thereby the analysis time. Subsequent eﬀorts were directed
to optimize the pH of the mobile phase and the concentration of the buﬀer solution as they had significant
717

718

EXP-3174 and candesartan in real subject sample after oral administration of fixed dose formulation containing 50 mg of losartan potassium and 12.5 mg
of hydrochlorothiazide hydrochloride.

Figure 3. MRM ion-chromatograms of (a) blank plasma with IS (candesartan), (b) losartan and EXP-3174 at LLOQ and candesartan, (c) losartan,
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impact on analyte retention, peak shape, and resolution. At pH above 5.0 the resolution between LOS and
HCTZ was aﬀected, which further deteriorated with increase in pH. Thus, to achieve greater reproducibility
and better chromatography, low pH buﬀers were tried. Better reproducibility and peak shape were observed in
acetonitrile:ammonium formate buﬀer, having pH 3.5 in 80:20 (v/v) ratio, but the signal to noise ratio for HCTZ
was not adequate at LLOQ level. Finally, a superior signal to noise ratio (≥ 22) and baseline resolution were
obtained for all the analytes by replacing formate buﬀer with 1.0% (v/v) formic acid together with acetonitrile
(15:85, v/v) having apparent pH 3.2 at a flow rate of 0.350 mL/min. There were no additional peaks due
to endogenous plasma components as observed in one report when short columns (50 mm) were used even
under MRM mode. 45 The chromatographic elution time for LOS, EXP-3174, HCTZ, CAN, and HFMZ was
1.37, 1.14, 1.87, 1.28, and 1.82 min, respectively, in a run time of 2.4 min (Figures 3a–3c and 4a–4c). The
area ratio of analyte/internal standard was consistent for at least 100 injections at five QC levels. The salient
chromatographic parameters like capacity factor and number of theoretical plates are presented in Table 1.
The resolution factor between LOS and EXP-3174, LOS and HCTZ, and EXP-3174 and HCTZ was 1.01, 2.08,
and 3.04, respectively. Ideally, a stable isotopically labeled analogue is preferred as an IS to account for any
changes in ionization eﬃciency, solvent evaporation, and for overall performance of the method. In the present
work general ISs were used that had structural similarity and belonged to the same class of drugs. CAN was
used for LOS and EXP-3174, while HFMZ was used to monitor HCTZ. Unlike a previous report employing
three separate ISs for the three analytes, 7 during method development trials it was evident that two ISs can
eﬀectively compensate any variability for improved accuracy and precision of the results.

Figure 4. MRM ion-chromatograms of (a) blank plasma with IS (hydroflumethiazide), (b) hydrochlorothiazide at LLOQ
and hydroflumethiazide, (c) hydrochlorothiazide and hydroflumethiazide in real subject sample after oral administration
of fixed dose formulation containing 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide hydrochloride.

719

SHAH et al./Turk J Chem

Table 1. Optimized mass spectrometer parameters, MRM transitions, and chromatographic performance.
Parameters

LOS

EXP-3174

HCTZ

CAN

HFMZ

Mass spectrometry parameters
Source dependent
Mode of analysis

Negative ionization

Capillary voltage (kV)

3.94

Cone voltage (V)

32

Extractor voltage (V)

5.0

RF lens (V)

0.0

Source temperature (°C)

110

Desolvation temperature (°C)

500

Desolvation gas flow (L/h)

700 ± 10

Cone gas flow (L/h)

150 ± 10

Quadrupole 1 and 3

Unit mass resolution

Analyzer parameters
LM 1/HM 1 resolution

15.0/15.0

Ion energy 1/ Ion energy 2

0.2/1.0

Entrance/Exit

–1.0/0.1

LM 2/ HM 2 resolution

14.0/14.0

Compound dependent
Cone voltage (V)

30

29

31

27

30

Collision energy (eV)

31

42

21

17

20

Dwell time (ms)

200

200

200

200

200

MRM transition (m/z)

421.2/127.0

435.2/157.0

295.9/268.8

439.1/309.9

329.9/239.0

Retention time (min)

1.37

1.14

1.87

1.28

1.81

Capacity factors

2.04

1.53

3.15

1.84

3.02

Theoretical plates

521

361

971

455

909

Chromatography characteristics

LOS: losartan; EXP-3174: losartan carboxylic acid; HCTZ: hydrochlorothiazide; CAN: candesartan; HFMZ: hydroflumethiazide; RF: radio frequency; LM: low mass; HM: high mass

Sample preparation is an area of concern with respect to the volume of biological sample used and for
high throughput analysis, especially with regard to the number of samples generated during clinical studies.
Kolocouri et al. 45 used an automated multiprobe work station for liquid transfer steps during 96-well–based
SPE after precipitation of plasma proteins with acetonitrile using 200 µ L plasma samples. Although this
method is well suited for high throughput applications, this facility may not be available in all labs. On the
other hand, the method reported by Goswami et al. 7 oﬀers a simplified oﬀ-line SPE procedure but employs large
plasma volume (500 µ L) for sample processing. Thus, to overcome these limitations and at the same time to
achieve higher sensitivity for the analytes we modified the reported procedure. 7 As all three analytes have high
protein binding ( ≥68%), the plasma proteins were precipitated with 5% (v/v) ortho-phosphoric acid instead
of acetonitrile 45 and use of ammonia solution 7 before loading the sample on the HLB cartridge. Further, the
720

LC-MS/MS; Nucleosil S-3 μm, 100 Å
(150 × 4.6 mm); 78% ACN and 22%
5.0 mM AA (v/v)

LC-MS/MS; Zorbax SBC18 (4.6 × 50
mm, 5 µm); MeOH:water, 5.0 mM AF
& 0.02%–0.05% FA under gradient
condition

LC-MS/MS; Discovery C18 (4.6 × 50
mm, 5 µm); ACN - AF buffer (pH 6.2
± 0.5; 2 ± 0.1 mM) (90:10, v/v)

LC-MS/MS; Inertsil ODS-3 (150 × 4.6
mm, 5 µm) for LOS & EXP-3174,
Venusil MP C18 (250 × 4.6 mm, 5
µm) for HCTZ; 0.1% FA- MeOH
(27:73 v/v, pH 2.7) for LOS, 0.1% FA MeOH (30:70 v/v, pH 2.7) for EXP3174, water- MeOH (60:40, v/v) for
HCTZ
UPLC-MS/MS; BEH C18 (50 × 2.1
mm, 1.7 µm); 1.0% (v/v) FA & ACN
(15:85, v/v)

1

2

3

4*

100 µL, SPE under acidic conditions of
o-phosphoric acid with Oasis HLB
extraction cartridges; 88.5–102.5 for all
three analytes

LOS: 200 µL, EXP-3174: 500 µL,
HCTZ: 200 µL;
PP for LOS, LLE for EXP-3174 &
HCTZ; NA

500 µL; SPE under alkaline condition
of ammonia with Oasis HLB
extraction cartridges; >80% for all
three analytes

750–1000 µL; SPE with MCX Oasis
plates; NA

200 µL;
96-well-format–based
SPE; NA

Plasma volume, Extraction technique;
Recovery

LOS: 0.5–500, EXP-3174: 1–750,
HCTZ: 0.25–150; 2.4 min

LOS: 5–800, EXP-3174: 5–750,
HCTZ: 1–150; 10.0 min

LOS: 2.54–1509.56,
EXP-3174: 3.27–1946.38, HCTZ:
2.10–410.40; 3.0 min

LOS: 2.02–807.20,
EXP-3174: 2.51–1002.49, HCTZ:
1.01–150.80; NA

LOS & EXP-3174: 1.00–400,
HCTZ: 0.500–200; 4.0 min

Linear range (ng/mL); Run time

MF: 0.939–1.050;
postcolumn
infusion study

96%–108%

NA

NA

NA

Matrix effect

Bioequivalence study of single dose
of 50 mg LOS + 12.5 mg HCTZ
combination tablet in 65 healthy
subjects; Incurred sample
reanalysis with 213 study samples

Bioequivalence study of single dose
of 50 mg LOS + 12.5 mg HCTZ
combination tablet in 40 healthy
male volunteers

Bioequivalence study of single dose
of 100 mg LOS + 25 mg HCTZ
combination tablet in 60 healthy
male subjects

Bioequivalence study of single dose
of 100 mg LOS + 12.5 mg HCTZ
combination tablet in 73 healthy
subjects

NA

Application

PM

47

7

46

45

Ref.

LOS: losartan; EXP-3174: losartan carboxylic acid; HCTZ: hydrochlorothiazide; PP: protein precipitation; LLE: liquid-liquid extraction; SPE: solid phase
extraction; ACN: acetonitrile; MeOH: methanol; AA: ammonium acetate; FA: formic acid; AF: ammonium formate; MF: matrix factor; PM: present method;
NA: data not available.
*Separate method for LOS, EXP-3174, and HCTZ

5

Detection technique;
Column; mobile phase

Sr.
No.

Table 2. Salient features of methods developed for the simultaneous determination of LOS, EXP-3174, and HCTZ in human plasma.

SHAH et al./Turk J Chem

721

SHAH et al./Turk J Chem

washing and elution steps were critically optimized without compromising the reproducibility and the recovery
of all three analytes. Sequential use of 1.0 mL of 5% methanol in water and 1.0 mL of 5 mM ammonium
formate ensured maximum removal of plasma components. Additionally, elution of analytes and ISs from the
cartridge was carried out with 900 µ L of acetonitrile:water (90:10, v/v) for optimum recovery in the range of
88.5%–102.5% for LOS, EXP-3174, and HCTZ. The salient features of the present method are compared with
those of methods developed for the simultaneous analysis of these three analytes in Table 2. As evident from
the results, the total analysis time and sensitivity are higher compared to these methods. 7,45−47 Moreover, this
is the first UPLC-MS/MS method for the simultaneous determination of these three analytes in human plasma.
Further, the plasma volume used for processing is also very low compared to existing methods. Karra et al. 24
have reported a sensitive method for the simultaneous determination of LOS, EXP-3174, and amlodipine in
human plasma. Moreover, the method was used for the pharmacokinetic analysis of only LOS and EXP-3174
in six healthy subjects. In the present work, sensitivity achieved for LOS (0.5 ng/mL) was identical, while for
EXP-3174 it was two times less compared to the previous work. 24 However, the volume of plasma required for
processing was half of that used in this reported work. 24 Additionally, these two analytes were not baseline
resolved and the analysis time was 2.5 min per sample, 24 whereas the chromatographic analysis time was 2.4
min in the present study.
Table 3. Intrabatch and interbatch precision and accuracy for losartan, EXP-3174, and hydrochlorothiazide.

QC level (nominal
concentration,
ng/mL)
Losartan
LLOQ QC (0.500)
LQC-2
(1.500)
LQC-1
(100.0)
MQC-2
(200.0)
MQC-1
(300.0)
HQC
(400.0)
EXP-3174
LLOQ QC (1.000)
LQC-2
(3.000)
LQC-1
(150.0)
MQC-2
(300.0)
MQC-1
(450.0)
HQC
(600.0)
Hydrochlorothiazide
LLOQ QC (0.250)
LQC-2
(0.750)
LQC-1
(30.0)
MQC-2
(60.0)
MQC-1
(90.0)
HQC
(120.0)

Intrabatch (n = 6; single batch)
Mean conc.
%
%
observed
CV
Accuracy
(ng/mL)

Interbatch (n = 30; 6 from each batch)
Mean conc.
%
%
found for 5
CV
Accuracy
batches (ng/mL)

0.481
1.498
102.7
206.8
303.0
379.8

2.88
1.62
3.84
4.06
2.92
3.76

96.2
99.9
102.7
103.4
101.0
95.0

0.482
1.493
102.8
194.9
294.8
404.6

2.36
1.39
2.17
5.09
4.68
3.75

96.4
99.5
102.8
97.5
98.3
101.2

1.017
3.093
144.7
295.9
448.5
612.0

4.93
1.72
3.72
2.37
1.87
3.11

101.7
103.1
96.5
98.6
99.7
102.0

0.991
3.041
151.2
282.7
463.6
586.4

1.25
1.97
3.36
3.17
2.25
1.54

99.1
101.4
100.8
94.2
103.0
97.7

0.247
0.759
29.2
61.8
89.4
118.5

1.43
2.11
3.18
4.47
3.15
2.30

98.8
101.2
97.3
103.0
99.3
98.8

0.255
0.768
29.6
59.6
86.9
122.1

1.56
3.18
4.05
2.26
4.71
3.23

102.0
102.4
98.7
99.3
96.6
101.8

CV: Coeﬃcient of variation; LLOQ: lower limit of quantitation; LQC: low quality control; MQC: medium quality control;
HQC: high quality control.
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2.2. Results for method validation
The autosampler carryover or memory eﬀects can have consequential eﬀects during chromatographic separation
and can dramatically limit the dynamic range and precision of the assay. The results obtained in this study
showed minimal carryover of analyte (≤ 0.15% of LLOQ area) in the extracted blank sample after injection of
upper limit of quantitation (ULOQ) sample for the analytes.
The method was highly selective for the determination of all the analytes. Representative MRM ion
chromatograms in Figures 3 and 4 of (a) blank human plasma with IS, (b) at LLOQ, and IS (c) in real subject
sample for LOS, EXP-3174, and HCTZ, respectively, demonstrate the selectivity of the method. The ion
chromatograms showed good peak shape with no interference peak of endogenous components at the retention
times of analytes and ISs. Moreover, there was no interference due to commonly used medications during
quantitation of the analytes under the MRM mode.
The calibration curves were linear over the validated concentration range of 0.5–500, 1.0–750, and 0.25–
150 ng/mL with the correlation coeﬃcient value, r2 ≥ 0.9989, ≥ 0.9988, and ≥ 0.9979 for LOS, EXP-3174, and
HCTZ, respectively. The equations for means (n = 5) of five calibration curves were y = (0.003342 ± 0.000047)
x – (0.000055 ± 0.000077), y = (0.002228 ± 0.000051) x+ (0.000055 ± 0.000144), and y = (0.011199 ±
0.000163) x + (0.000194 ± 0.000286) for LOS, EXP-3174, and HCTZ, respectively. The accuracy and precision
(% CV) for the calibration curve standards were 97.7%–102.7% and 0.95–5.45 for LOS, 98.3%–101.3% and 1.18–
7.24 for EXP-3174, and 96.9%–104.5% and 1.28–5.59 for HCTZ, respectively. The LLOQ in the standard curve
for the analytes was measured at a signal-to-noise ratio (S/N) of ≥ 22. The intrabatch and interbatch precision
(% CV) across six quality control samples ranged from 1.25 to 5.09 over the analytical range and the accuracy
was within 94.2% to 103.4% for all the analytes (Table 3).

Table 4. Extraction recovery of losartan, EXP-3174, and hydrochlorothiazide from human plasma.

QC level

Losartan
Area response
A

LQC-2
LQC-1
MQC-2
MQC-1
HQC
QC level
LQC-2
LQC-1
MQC-2
MQC-1
HQC

B

924
913
65,512
64,534
123,577
126,689
189,764
188,985
262,359
252,157
Candesartan (IS)
Area response

Extraction
recovery,
% (B/A)
98.8
98.5
102.5
99.6
96.1

A

B

182,306
191,242
196,076
194,876
197,148

184,810
194,126
189,010
195,762
187,014

EXP-3174
Area response
A

B

1193
60,123
137,734
210,049
251,929

1182
59,182
128,093
197,866
246,387
Extraction
recovery, %
(B/A)
101.4
101.5
96.4
100.4
94.8

Extraction
recovery,
% (B/A)
99.0
98.4
93.0
94.2
97.8

Hydrochlorothiazide
Area response
A

B

Extraction
recovery,
% (B/A)
93.5
96.3
94.4
91.4
88.5

1379
1289
59,470
57,270
121,473 114,670
173,718 158,778
257,549 227,931
Hydroflumethiazide (IS)
Area response
Extraction
recovery,
A
B
% (B/A)
111,874 106,728
95.4
125,652 112,835
89.8
114,223 109,882
96.2
120,396 111,728
92.8
122,379 105,491
86.2

LQC: low quality control; MQC: medium quality control; HQC: high quality control;
A: Mean area response of six replicate samples prepared by extracting spiked blank plasma;
B: Mean area response of six replicate samples prepared by spiking in extracted blank plasma
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The mean extraction recovery for all the analytes and ISs is presented in Table 4. The recovery was
96.1%–102.5% for LOS, 93.0%–99.0% for EXP-3174, and 88.5%–96.3% for HCTZ across five QC levels. The
presence of unmonitored, co-eluting compounds from the matrix may result in ion suppression/enhancement,
decrease/increase in sensitivity of analytes over a period of time, increased baseline, and drift in retention time
and thus can compromise the overall reliability of a validated method. In the present work, no ion suppression
eﬀects were observed under the optimized sample preparation and chromatographic conditions. Results of the
postcolumn analyte infusion experiment showed negligible ion suppression or enhancement at the retention time
of analytes and ISs (Figure 5a–5e). Further, quantitative evaluation of the matrix eﬀect was also carried out
for all the analytes and ISs from the peak area response and expressed as matrix factors as shown in Table 5.
The IS-normalized matrix factors (analyte/IS) were 0.92–0.98 for LOS, 0.91–1.06 for EXP-3174, and 0.93–1.09
for HCTZ. Further, the matrix eﬀect was also checked in lipemic and hemolyzed plasma samples in addition to
normal K 3 EDTA plasma by calculating the precision (% CV) in the measurement of the slope of calibration
curves. The % CV values of the slopes of calibration lines in ten diﬀerent plasma lots were 2.32, 2.29, and 3.19
for LOS, EXP-3174, and HCTZ, respectively.
Table 5. Matrix factor for losartan, EXP-3174, and hydrochlorothiazide.

Losartan

EXP-3174

Hydrochlorothiazide

QC level

Area response

LQC-2
LQC-1

A
967
64,340

B
913
64,534

Matrix
factor
(B/A)
0.944
1.003

Area response

B
1182
59,182

Matrix
factor
(B/A)
0.941
0.942

A
1372
54,908

B
1289
57,270

Matrix
factor
(B/A)
0.939
1.043

MQC-2

127,325

126,689

0.995

125,704

128,093

1.019

109,837

114,670

1.044

MQC-1

193,632

188,985

0.976

188,443

197,866

1.050

164,707

158,778

0.964

HQC

258,888

252,157

0.974

251,415

246,387

0.980

219,586

227,931

1.038

Area response
A
1256
62,825

Candesartan

Hydroflumethiazide

Area response
QC level

A

B

LQC-2
LQC-1
MQC-2
MQC-1
HQC

180,478
188,106
187,138
197,739
182,809

184,810
194,126
189,010
195,762
187,014

Matrix
factor
(B/A)
1.024
1.032
1.010
0.990
1.023

Area response
A

B

111,757
118,275
107,727
108,896
110,461

106,728
112,835
109,882
111,728
105,491

Matrix
factor
(B/A)
0.955
0.954
1.020
1.026
0.955

LQC: low quality control; MQC: medium quality control; HQC: high quality control;
A: Mean area response of six replicate samples prepared in mobile phase (neat samples);
B: Mean area response of six replicate samples prepared by spiking in extracted blank plasma

The stability of all the analytes in plasma was established at appropriate temperatures and storage
periods required for clinical analysis. The stock solutions kept for short-term and long-term stability of analytes
and ISs were found stable at room temperature up to 7 h and for a minimum period of 7 days, respectively.
The detailed results for bench top stability, wet extracts, dry extracts, processed sample, and freeze-thaw and
long-term stability of the analytes are summarized in Table 6. The precision and accuracy results found for
method ruggedness with diﬀerent columns and analysts were within 3.25% to 6.01% and 93.5% to 102.4% for
LOS, 2.53% to 4.31%, and 96.8% to 100.9% for EXP-3174 and 4.17% to 5.95% and 98.3% to 104.7% for HCTZ,
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Figure 5. Postcolumn analyte infusion MRM LC-MS/MS chromatograms for (a) losartan, (b) EXP-3174, (c) candesartan, (d) hydrochlorothiazide, and (e) hydroflumethiazide.

respectively. The dilution reliability test was performed to validate analyte concentrations that are above the
ULOQ of the linear range, especially with regard to clinical samples. The precision (% CV) and accuracy values
for 1/10th dilution were 2.61–6.38 and 93.5–106.3 for all the analytes.
2.3. Application of the method in healthy subjects and incurred sample reanalysis
The proposed UPLC-MS/MS method was successfully applied for a comparative bioavailability study of fixed
dose tablet formulation containing 50 mg of LOS and 12.5 mg of HCTZ in 65 healthy subject samples under
fasting. The mean plasma concentration vs. time profiles of LOS, EXP-3174, and HCTZ after oral administration of the drugs are presented in Figure 6. The important pharmacokinetic parameters of the study like
C max , AUC 0−48 , AUC 0−inf , T max , K el , and t 1/2 were calculated for LOS, EXP-3174, and HCTZ and the
values for test and reference formulations are given in Table 7. The results obtained were in good agreement
with reported studies in Indian 7 and Chinese subjects. 47 The ratios of mean log-transformed parameters and
their 90% confidence intervals varied from 90.7% to 101.9% for LOS, 95.3% to 107.2% for EXP-3174, and 94.3%
to 104.2% for HCTZ, which are within the acceptance range of 80%–125%. From these results the two formulations can be considered equivalent for both the rate and extent of drug absorption. Thus, the developed assay
procedure for LOS, EXP-3174, and HCTZ in human plasma samples demonstrates the precision and sensitivity
needed for pharmacokinetic studies of these drugs.
Incurred sample reanalysis (ISR) is conducted to assess the reproducibility of a validated method by
reanalysis of selected subject samples after initial analysis is completed. 48 A well-established bioanalytical
method with an integrated ISR plan can lead to continuous review of assay performance. The ISR test reinforces
the confidence in a method if reproducibility is demonstrated in the study sample analysis and has now become
mandatory for bioanalytical assays. The ISR results are expressed as percentage change, where
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Table 6. Stability of losartan, EXP-3174, and hydrochlorothiazide in human plasma under diﬀerent conditions.

Losartan
EXP-3174
Mean
of
six
Mean of six
Storage conditions
%
stability samples
stability samples
Change
(ng/mL) ± SD
(ng/mL) ± SD
Bench top stability at room temperature; 14 h
LQC-2
1.516 ± 0.012
1.07
2.89 ± 0.176
LQC-1
102.4 ± 5.68
2.40
147.3 ± 10.32
HQC
397.9 ± 15.9
–0.53
615.6 ± 12.87
Wet extract stability; 5 ◦ C, 24 h
LQC-2
1.474 ± 0.018
–1.73
3.13 ± 0.065
LQC-1
106.7 ± 7.13
6.70
152.3 ± 9.67
HQC
408.0 ± 15.2
2.00
592.5 ± 14.32
Dry extract stability at 5 ◦ C, 62 h
LQC-2
1.521 ± 0.019
1.40
3.06 ± 0.069
LQC-1
98.9 ± 6.25
–1.10
155.4 ± 8.75
HQC
410.2 ± 14.3
2.55
608.9 ± 12.40
Processed sample stability at 25 ◦ C, 42 h
LQC-2
1.472 ± 0.024
–1.87
3.05 ± 0.197
LQC-1
104.2 ± 7.33
4.20
146.0 ± 7.62
HQC
413.5 ± 24.0
3.38
618.0 ± 11.94
Freeze & thaw stability in plasma; 6 cycles, –20 ◦ C
LQC-2
1.535 ± 0.019
2.33
2.97 ± 0.034
LQC-1
105.4 ± 5.97
5.40
156.6 ± 9.64
HQC
386.9 ± 13.9
–3.28
606.3 ± 18.66
Freeze & thaw stability in plasma; 6 cycles, –70 ◦ C
LQC-2
1.531 ± 0.018
2.07
3.11 ± 0.412
LQC-1
98.9 ± 4.44
–1.10
158.7 ± 8.14
HQC
407.3 ± 11.3
1.83
594.2 ± 19.36
Long-term stability in plasma; 60 days, –20 ◦ C
LQC-2
1.481 ± 0.015
–1.27
3.18 ± 0.126
LQC-1
104.7 ± 6.49
4.70
148.9 ± 7.14
HQC
375.9 ± 15.6
–6.03
617.6 ± 16.26
◦
Long-term stability in plasma; 60 days, –70 C
LQC-2
1.571 ± 0.021
4.73
2.88 ± 0.181
LQC-1
97.4 ± 6.43
–2.60
151.3 ± 7.74
HQC
406.8 ± 17.4
1.70
595.6 ± 12.68

%
Change

Hydrochlorothiazide
Mean of six
%
stability samples
Change
(ng/mL) ± SD

–3.67
–1.80
2.60

0.745 ± 0.022
30.5 ± 4.015
118.8 ± 6.97

–0.67
1.67
–1.00

4.33
1.53
–1.25

0.768 ± 0.016
28.6 ± 6.33
122.1 ± 7.69

2.40
–4.67
1.75

2.00
3.60
1.48

0.758 ± 0.017
32.0 ± 4.75
126.5 ± 5.16

1.07
6.67
5.42

1.67
–2.67
3.00

0.757 ± 0.018
30.7 ± 6.31
114.6 ± 8.65

0.93
2.33
–4.50

–1.00
4.40
1.05

0.727 ± 0.019
29.6 ± 4.52
121.8 ± 5.35

–3.07
–1.33
1.50

3.67
5.80
–0.97

0.781 ± 0.011
29.4 ± 3.47
121.0 ± 8.32

4.13
–2.00
0.83

6.00
–0.73
2.93

0.741 ± 0.014
30.5 ± 1.32
116.7 ± 4.08

–1.320
1.67
–2.75

–4.00
0.87
–0.73

0.773 ± 0.015
28.3 ± 3.68
123.6 ± 4.89

3.07
–5.67
3.00

LQC: low quality control; HQC: high quality control; SD: Standard deviation; n: Number of replicates at each level

% Change =

Repeat value - Original value
× 100
Mean of original and repeat values

In the present work, the assay reproducibility test conducted with 213 incurred samples showed % change within
±18% of the initial analysis results for all the analytes, which confirms the reproducibility of the proposed
method.
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Table 7. Mean pharmacokinetic parameters following oral administration of 50 mg losartan and 12.5 mg hydrochlorothiazide test and reference formulation to 65 healthy Indian subjects under fasting conditions.
Mean ± SD
Parameter
Losartan
Cmax (ng/mL)
AUC 0−48 (h. ng/mL)
AUC 0−inf (h. ng/mL)
Tmax (h)
t1/2 (h)
Kel (1/h)
EXP-3174
Cmax (ng/mL)
AUC 0−48 (h. ng/mL)
AUC 0−inf (h. ng/mL)
Tmax (h)
t1/2 (h)
Kel (1/h)
Hydrochlorothiazide
Cmax (ng/mL)
AUC 0−48 (h. ng/mL)
AUC 0−inf (h. ng/mL)
Tmax (h)
t1/2 (h)
Kel (1/h)

90% CI (LowerUpper)

Power

Intrasubject
variation,
% CV

Test

Reference

Ratio (test/
reference),%

243 ± 53
517 ± 194
535 ± 209
1.46 ± 0.29
2.12 ± 1.05
0.322 ± 0.007

251 ± 69
552 ± 213
573 ± 256
1.52 ± 0.35
2.37 ± 1.11
0.301 ± 0.006

96.9
93.9
94.1
–
–
–

93.3–101.9
90.7–97.8
91.1–98.2
–
–
–

0.9991
0.9996
0.9995
–
–
–

9.14
8.27
9.63
–
–
–

455 ± 152
2147 ± 784
2235 ± 739
3.28 ± 0.33
4.05 ± 0.84
0.176 ± 0.021

463 ± 178
2102 ± 693
2173 ± 556
3.15 ± 0.42
4.96 ± 0.95
0.140 ± 0.015

98.4
101.9
102.6
–
–
–

95.3–102.9
97.7–104.8
98.1–107.2
–
–
–

0.9998
0.9994
0.9995
–
–
–

5.44
7.97
9.13
–
–
–

65.32 ± 23.4
417 ± 134
455 ± 139
2.40 ± 0.18
9.12 ± 1.20
0.0760 ± 0.003

66.41 ± 19.3
425 ± 153
463 ± 156
2.53 ± 0.22
9.08 ± 1.25
0.0763 ± 0.004

98.5
98.1
97.9
–
–
–

94.3–103.9
96.7–103.8
95.1–104.2
–
–
–

0.9998
0.9994
0.9995
–
–
–

4.14
6.17
6.43
–
–
–

C max : Maximum plasma concentration; AUC 0−t : Area under the plasma concentration-time curve from zero hour to
48 h;
AUC 0−inf : Area under the plasma concentration-time curve from zero hour to infinity; T max : Time point of maximum
plasma concentration;
t 1/2 : Half life of drug elimination during the terminal phase; K el : Elimination rate constant; SD: Standard deviation;
CI: confidence interval;
CV: coeﬃcient of variation

3. Experimental
3.1. Chemicals and materials
Reference standards of LOS potassium (99.6%) and HCTZ (99.3%) were obtained from United States Pharmacopeia (Rockville, MD, USA). EXP-3174 (98.6%), CAN (99.6%), and HFMZ (99.4%) were procured from
Toronto Research Chemicals Inc. (Ontario, Canada). Suprapure grade ortho-phosphoric acid, ammonium
formate, and formic acid were obtained from Merck Specialties Pvt. Ltd. (Mumbai, India). HPLC grade
methanol and acetonitrile were obtained from Mallinckrodt Baker, S.A.de C.V. (Estado de Mexico, Mexico).
Oasis HLB (1 cc, 30 mg) extraction cartridges were from Waters Corporation (Milford, MA, USA). Water used
in the study was prepared using the Milli-Q water purification system from Millipore (Bangalore, India). Blank
human plasma in K 3 EDTA was obtained from Supratech Micropath (Ahmedabad, India) and was stored at
–20 ◦ C until use.
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Figure 6. Mean plasma concentration-time profiles of losartan, EXP-3174, and hydrochlorothiazide after oral administration of 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide hydrochloride fixed dose tablet formulation
to 65 healthy Indian male subjects under fasting.

3.2. Liquid chromatography and mass spectrometric conditions
The chromatographic analysis of LOS, EXP-3174, and HCTZ was carried out on a Waters Acquity UPLC
system (Milford, MA, USA) employing a BEH C18 (50 × 2.1 mm, 1.7 µ m) column, maintained at 35 ◦ C. The
mobile phase was prepared in premixed solvents consisting of 1.0 % (v/v) formic acid in water and acetonitrile
(15:85, v/v). The mobile phase was pumped at a flow rate of 0.350 mL/min. The injection volume was set
at 10 µ L. The sample manager temperature was maintained at 5 ◦ C with an alarm band of ±3 ◦ C and
the average pressure of the system was 6000 psi. Detection and quantitation of analytes and ISs was carried
out using multiple reaction monitoring (MRM) for deprotonated precursor → product ion transitions on a
Quattro Premier XE mass spectrometer from Waters – Micro Mass Technologies (Milford, MA, USA), in the
negative ionization mode. Source dependent and compound dependent mass parameters optimized and MRM
transitions for analytes and ISs are summarized in Table 1. MassLynx software version 4.1 was used to control
all parameters of UPLC and MS.
3.3. Calibrators and quality control samples
Separate stock solutions (1.0 mg/mL) of LOS, EXP-3174, and HCTZ were prepared by dissolving their accurately weighed amounts in methanol. Their intermediate solutions of 100.0 µ g/mL for LOS and EXP-3174 and
50.0 µ g/mL for HCTZ were prepared in methanol:water (50:50, v/v). Calibration standards (CSs) and quality
control (QC) samples were made by spiking blank plasma with suitable volumes of working solutions prepared
from intermediate solutions for all the analytes. The mixed CSs in plasma were prepared at 0.50, 1.0, 2.5, 5.0,
10.0, 25.0, 75.0, 150, 300, and 500 ng/mL for LOS; 1.0, 2.0, 5.0, 10.0, 20.0, 50.0, 100, 250, 500, and 750 ng/mL
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for EXP-3174; and 0.25, 0.50, 1.0, 2.0, 5.0, 15.0, 30.0, 50.0, 100, and 150 ng/mL for HCTZ. QC samples were
prepared at 400.0/600.0/120.0 ng/mL (HQC, high quality control), 300.0/450.0/90.0 ng/mL (MQC-1, medium
quality control-1), 200.0/300.0/60 ng/mL (MQC-2, medium quality control-2), 100.0/150.0/30.0 ng/mL (LQC-1,
low quality control-1), 1.5/3.0/0.750 ng/mL (LQC-2, low quality control-2), and 0.50/1.00/0.25 ng/mL (LLOQ
QC, lower limit of quantitation quality control) for LOS/EXP-3174/HCTZ, respectively. The stock solutions of
ISs (1.0 mg/mL) were prepared by dissolving requisite amounts in methanol. Their combined working solutions
(500 ng/mL for CAN and 50 ng/mL for HFMZ) were prepared by appropriate dilution of their stock solutions
in methanol:water (50:50, v/v). All standard stock and working solutions used for spiking were stored at 5 ◦ C,
while CSs and QC samples in plasma were kept at –70 ◦ C until use.
3.4. Sample extraction protocol
Prior to analysis, all calibration and quality control samples were thawed and allowed to equilibrate at room
temperature. To an aliquot of 100 µ L of spiked plasma sample/subject sample, 50 µ L of internal standard
was added and vortexed for approximately 10 s. Further, 500 µ L of 5% (v/v) ortho-phosphoric acid was added
and vortexed for another 10 s. The samples were then loaded on Oasis HLB extraction cartridges that were
preconditioned with 1.0 mL of methanol followed by 1.0 mL of water. Thereafter the cartridges were washed
with 1.0 mL of 5% methanol in water and then with 1.0 mL of 5 mM ammonium formate followed by drying for
2 min by applying 1.72 × 10 5 Pa positive pressure of nitrogen at 2.4 L/min flow rate.

Elution of analytes and

ISs from the cartridges was carried out with 500 µ L of acetonitrile:water (90:10, v/v) into prelabeled tubes. The
eluate was evaporated to dryness in a thermostatically controlled water bath maintained at 40 ◦ C under a gentle
stream of nitrogen for 5 min. After drying, the residue was reconstituted in 100 µ L of reconstitution solution
[10 mM ammonium formate: acetonitrile (20:80, v/v)] and 10 µ L was used for injection in the chromatographic
system.
3.5. Validation procedures
Method validation procedures were based on USFDA guidelines 49 and are similar to those in our previous
work. 50 A system suitability test was done to authenticate optimum instrument performance (e.g., sensitivity
and chromatographic retention) and was performed by analyzing a reference standard solution prior to running
the analytical batch. In this test, six consecutive injections of aqueous standard mixture of analytes (at ULOQ)
and IS were injected at the start of each batch during method validation. The precision (% CV) in the
measurement of area response and retention time was assessed. The precision (% CV) of the system suitability
test was observed in the range of 0.13% to 0.24% for the retention time and 0.85% to 2.96% for the area
response for all the analytes and ISs. Additionally, the accuracy in the measurement of solution concentration
was also evaluated. System performance was checked by calculating the signal to noise ratio for quantifying
LLOQ sample for all the analytes. In this experiment, one extracted blank (without analytes and IS) and one
processed LLOQ sample with IS was injected at the beginning of each analytical batch. The signal to noise
ratio for system performance was ≥ 22 for all the analytes. Autosampler carryover was evaluated by sequentially
injecting aqueous standard of analytes, mobile phase, extracted blank plasma, ULOQ sample, two extracted
blank plasma samples, LLOQ sample, and extracted blank plasma at the start of each batch.
Selectivity of the method towards endogenous plasma matrix components was verified in ten batches (8
normal lots of K 3 EDTA, 1 hemolyzed, and 1 lipemic) of blank human plasma. The area response of analytes
and ISs at their respective retention times was compared with the area response observed in the LLOQ samples,
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prepared from the same lot of blank plasma. In addition, interference due to some commonly used medications
like paracetamol, chlorpheniramine maleate, diclofenac, caﬀeine, acetylsalicylic acid, and ibuprofen by human
volunteers was also checked. Their stock solutions (100 µ g/mL) were prepared in methanol. Further, their
working solutions (100 ng/mL) were prepared in methanol:water (50:50, v/v) and 10 µ L was injected to check
for any possible interference at the retention time of analytes and ISs.
The linearity of the method was determined by analysis of five linearity curves containing ten nonzero
concentrations in the concentration range of 0.5–500 ng/mL for LOS, 1.0–750 ng/mL for EXP-3174, and 0.25–
150 ng/mL for HCTZ. The area ratio response for analyte/IS obtained from multiple reaction monitoring was
used for regression analysis. The simple linear equation y = m x+ c was used for regression analysis of spiked
plasma calibration standards with reciprocal of the drug concentration (1/concentration) as a weighing factor
(1/x2 ) . The lowest standard on the calibration curve was accepted as the LLOQ if the analyte response was
at least ten times more than that of extracted blank plasma. 49
Intrabatch accuracy and precision were determined by analyzing six replicates of QC samples along with
calibration curve standards on the same day. The interbatch accuracy and precision were assessed by analyzing
five precision and accuracy batches on three consecutive days. Sample injection reproducibility was also checked
by reinjecting one entire validation batch. Reinjection reproducibility for extracted samples was also checked
by reinjection of an entire analytical run after storage at 5 ◦ C.
Ion suppression/enhancement eﬀects on MRM LC-MS/MS sensitivity were evaluated by postcolumn
analyte infusion technique. A standard solution containing LOR, EXP-3174, HCTZ (at MQC-1 level), and
ISs was infused postcolumn into the mobile phase at 10 µ L/min. Aliquots of 10 µ L of extracted control
blank plasma sample were then injected into the column and chromatograms were acquired for the analytes.
Extraction recovery of the analytes and ISs from human plasma was evaluated in six replicates by comparing
the mean peak area responses of preextraction fortified samples to those of postextraction fortified samples
representing 100% recovery. The matrix eﬀect, expressed as matrix factors (MFs), was assessed by comparing
the mean area response of postextraction fortified samples with the mean area of solutions prepared in mobile
phase solutions (neat standards). IS-normalized MFs (analyte/IS) were calculated to assess the variability of
the assay due to matrix eﬀects. Relative matrix eﬀect was assessed from the precision (% CV) values of the
slopes of the calibration curves prepared from ten diﬀerent plasma lots/sources. To prove the absence of the
matrix eﬀect, % CV should be less than 3%–4% as recommended for method applicability to support clinical
studies. 51
The standard stock solutions of analytes and ISs were evaluated for short-term and long-term stability
at 25 ◦ C and 5 ◦ C, respectively. The analyte stability in spiked plasma samples was evaluated by measuring
the area ratio response (analyte/IS) of stability samples against freshly prepared standards having identical
concentration. The % change was determined using the expression
% Change =

Mean stability samples - Mean comparison samples
× 100
Mean comparison samples

Bench top (at room temperature), wet extract at 5 ◦ C, dry extract at 5 ◦ C, processed sample stability at room
temperature, and freeze-thaw (–20 ◦ C and –70 ◦ C) and long-term (–20 ◦ C and –70 ◦ C) stability of analytes in
plasma were studied at three QC levels using six replicates. The stability samples were quantified against freshly
prepared quality control samples. Stability data were acceptable if the % CV of the replicate determinations
did not exceed 15.0% and the mean accuracy value was within ± 15.0% of the nominal value.
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A ruggedness study is usually performed to facilitate transfer of a method to another laboratory; however,
it can also be carried out during method development to assess the method’s inherent variability. It provides
a more rigorous approach for assessing method precision than a comparative intermediate precision study
normally performed as part of method validation. In the present work, method ruggedness was evaluated to
check any possible variation from analyst to analyst and column to column (two diﬀerent columns of the same
make having diﬀerent batch numbers) using the same samples (two precision and accuracy batches), while
keeping the optimized method parameters constant. The degree of reproducibility was evaluated and expressed
in terms of precision (% CV). The ability to dilute samples that have concentrations above the upper limit
of the calibration range was validated by analyzing six replicate samples containing 1000/1500/300 ng/mL
LOS/EXP-3174/HCTZ after ten-fold dilution, respectively. The precision and accuracy for dilution reliability
were determined by comparing the samples against freshly prepared calibration curve standards.
3.6. Bioequivalence study and incurred sample reanalysis
A bioequivalence study was performed in 65 healthy subjects with fixed dose 50 mg LOS potassium + 12.5
mg HCTZ hydrochloride test (Generic Company, India) and reference (HYZAAR, Merck Sharp & Dohme, NJ,
USA) tablet formulation. The primary target variables of the study were C max , AUC 0−48 , and AUC 0−inf ,
which were analyzed using the confidence interval approach. All the subjects were informed of the aim and risk
involved in the study and written consent was obtained. An Independent Ethics Committee approved the study
protocol. The study was performed as per the guidelines of the International Conference on Harmonization and
USFDA. 52 The health checkup for all subjects was done by general physical examination, ECG, and laboratory
tests like hematology, biochemistry, and urine examination. All subjects were negative for HIV, HBsAg, and
HCV. They were orally administered a single dose of test/reference formulation with 240 mL of water after a
wash-out period of 7 days. Blood samples were collected in vacutainers containing K 3 EDTA as anticoagulant
at predose (0.0 h), 0.17, 0.33, 0.50, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0,
16.0, 24.0, 30.0, 36.0, and 48.0 h of administration of drug. Blood samples were centrifuged at 3200 rpm for
10 min and plasma was separated and stored at –70 ◦ C until use. The pharmacokinetic parameters of LOS,
EXP-3174, and HCTZ were estimated by noncompartmental model using WinNonlin software version 5.2.1
(Pharsight Corporation, Sunnyvale, CA, USA). To determine whether the test and reference formulations were
pharmacokinetically equivalent, C max , AUC 0−48 , and AUC 0−inf and their ratios (test/reference) using log
transformed data were assessed. The drug formulations were considered pharmacokinetically equivalent if the
diﬀerence between the compared parameters was statistically nonsignificant (P ≥ 0.05) and the 90% confidence
intervals (CIs) for these parameters were within 80% to 125%.
The method reproducibility was verified by reanalysis of 213 incurred samples and the results were
compared with original study samples. The acceptance criterion was based on two-thirds of the original results
and repeat results should be within 20% of each other. 48
3.7. Conclusion
As compared with earlier LC-MS/MS methods for the determination of these drugs, the proposed UPLC-MS/MS
oﬀers several advantages such as higher sensitivity, short analysis time, small plasma volume for processing,
and low consumption of toxic organic solvents. The extraction method was suitably optimized for quantitative
and reproducible recovery of the analytes having diﬀerent physico-chemical properties. The matrix eﬀect was
extensively studied through postcolumn infusion, postextraction spiking, and calculation of slope of calibration
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lines for the relative matrix eﬀect. The method showed acceptable accuracy and precision in the measurement of
these drugs in clinical samples. Finally, the method reproducibility was successfully demonstrated by reanalysis
of incurred study samples, which has not been reported in previous methods.
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